Health Trials

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

ConditionObesity or Overweight
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-99
SponsorAmgen

About this trial

Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.

Eligibility criteria

Qualifiers

Body Mass Index (BMI) ≥ 25 at screening.

Weight loss of ≥ 10% on weekly GLP-1 RA.

Stable body weight.

Stable dose of GLP-1RA.

Disqualifiers

Obesity induced by other endocrine disorders (ex: Cushing's syndrome).

Previous or planned surgical, endoscopic or device-based treatment for obesity.

History of malignancy.

Type 1/Type 2 diabetes mellitus (DM).

Trial design

Treatments tested in this trial

  • Maridebart Cafraglutide

Treatment groups

300 Participants
are divided into 2 treatment groups

Locations

43
Puerto Rico
Puerto Rico Medical Research Inc.00717, Ponce Puerto Rico
United States
Alabama
Cahaba Research, Inc.35124, Pelham United States
Arizona
Arizona Clinical Trials85224, Chandler United States
Epic Medical Research - Sun City85351, Sun City United States

Sponsors and collaborators

Amgen

Lead sponsor

Source ClinicalTrials.gov